Moderna will not be developing a vaccine to protect against bird flu — at least on the federal government’s dime. The U.S.

Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.

The department cited Moderna’s use of the messenger RNA technology, which it said “remains under-tested,” for the ...

The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing ...

Messenger RNA technology offers a faster way to develop vaccines to address or prepare for pandemics, and Moderna’s vaccine ...

The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...

HHS has notified Moderna that it is canceling a nearly $600 million contract for vaccines for flu strains that could trigger ...

With the continued use of COVID-19 vaccines worldwide, there’s a massive amount of data that shows mRNA shots are safe.

The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.